Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MCRPC (metastatic Castration-resistant Prostate Cancer)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT02362620
What this trial is testing

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.

Who this might be right for
Advanced Prostate CancerCabazitaxelDocetaxel
Centro Nacional de Investigaciones Oncologicas CARLOS III 402
Testing effectiveness (Phase 2)Looking for participantsNCT04986423
What this trial is testing

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics 200
Early research (Phase 1)Looking for participantsNCT06784193
What this trial is testing

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)+3 more
Olema Pharmaceuticals, Inc. 180
Testing effectiveness (Phase 2)Looking for participantsNCT05521412
What this trial is testing

EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate Cancer
Peter MacCallum Cancer Centre, Australia 66
Early research (Phase 1)Active Not RecruitingNCT05806814
What this trial is testing

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
University of Oklahoma 15
Not applicableLooking for participantsNCT06529549
What this trial is testing

Efficacy and Safety of Organoid-Based Drug Sensitivity Screening to Guide the Treatment of mCRPC Patients Progressed After First-line Treatment

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Sun Yat-sen University 30
Testing effectiveness (Phase 2)Study completedNCT04408924
What this trial is testing

Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Eli Lilly and Company 44
Large-scale testing (Phase 3)Ended earlyNCT04844749
What this trial is testing

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Who this might be right for
Metastatic Castration-resistant Prostate CancerAndrogen Resistant Prostatic Cancer
Veru Inc. 105
Testing effectiveness (Phase 2)Looking for participantsNCT07332455
What this trial is testing

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Who this might be right for
Neoplasms, Prostate
GlaxoSmithKline 54
Not applicableStudy completedNCT05520138
What this trial is testing

Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Pfizer 5,506
Testing effectiveness (Phase 2)UnknownNCT05955209
What this trial is testing

Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Peking University Cancer Hospital & Institute 40
Testing effectiveness (Phase 2)WithdrawnNCT02420587
What this trial is testing

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer
M.D. Anderson Cancer Center
Not applicableStudy completedNCT05968599
What this trial is testing

Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Pfizer 2,731
Testing effectiveness (Phase 2)Looking for participantsNCT07730021
What this trial is testing

ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors

Who this might be right for
Locally Advanced or Metastatic Solid Tumors
Astellas Pharma Global Development, Inc. 392
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07104643
What this trial is testing

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）

Who this might be right for
mCRPC
TYK Medicines, Inc 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT05682443
What this trial is testing

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
OncoC4, Inc. 148
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07737925
What this trial is testing

LuX: Xaluritamig in Participants With Metastatic Castrate Resistant Prostate Cancer and Suboptimal Response to Lutetium 177 Vipivotide Tetraxetan

Who this might be right for
Prostate CancerMetastatic Castrate Resistant Prostate Cancer
Thomas Jefferson University 30
Post-approval studies (Phase 4)Active Not RecruitingNCT04597125
What this trial is testing

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Bayer 654
Large-scale testing (Phase 3)Active Not RecruitingNCT04647526
What this trial is testing

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company 455
Not applicableStudy completedNCT02899104
What this trial is testing

Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Bayer 200
Next Page